A Study of MET233 in Individuals With Obesity or Overweight
Completed · Phase 1 · Has a placebo group
Conditions studied: Obesity and Overweight
In brief
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity. This study will be conducted in four parts: * Part A will evaluate single ascending doses of MET233 or placebo. * Part B will evaluate multiple ascending doses, with participants receiving five once-weekly doses of MET233 or placebo. * Part C will evaluate once-weekly dosing of MET233 or placebo for 12 weeks, followed by a single higher, potential monthly dose. * Part D will evaluate a longer dosing schedule, in which participants will receive twelve once-weekly doses, followed by three monthly doses of MET233 or placebo. Participants in this part will be followed for 14 weeks after the final dose.
Key facts
- Study ID
- NCT07022977
- Run by
- Pfizer
- People needed
- 144
- Starts
- 2024-11-06
- Expected to finish
- 2026-04-21
- Last updated by the study team
- 2026-05-26
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Adult (≥18 to ≤70 years) male and female participants with obesity or overweight (BMI 27.0 kg/m2 to 38.0 kg/m2, inclusive) but otherwise healthy.
You may not qualify if…
- Female who is lactating or who is pregnant according to the pregnancy test at the Screening visit or prior to the first study drug administration
- Seated blood pressure higher than 160/95 mmHg at the Screening visit
- Elevated resting pulse greater than 100 beats per minute at Screening visit
- Presence of clinically significant ECG abnormalities
- Diagnosis of diabetes (type 1 or type 2)
- Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration
- Obesity induced by endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome).
Where it is running
- Altasciences Clinical Los Angeles, Inc. — Cypress, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.